nodes	percent_of_prediction	percent_of_DWPC	metapath
Fulvestrant—NR1H4—skull—peripheral nervous system neoplasm	0.0261	0.491	CbGeAlD
Fulvestrant—ESR2—Validated nuclear estrogen receptor beta network—SMARCB1—peripheral nervous system neoplasm	0.0182	0.116	CbGpPWpGaD
Fulvestrant—NR1H4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.0076	0.0484	CbGpPWpGaD
Fulvestrant—ESRRA—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.00565	0.036	CbGpPWpGaD
Fulvestrant—EPHX2—parotid gland—peripheral nervous system neoplasm	0.0055	0.104	CbGeAlD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—PHOX2B—peripheral nervous system neoplasm	0.00532	0.0339	CbGpPWpGaD
Fulvestrant—ESRRA—trigeminal ganglion—peripheral nervous system neoplasm	0.0051	0.0961	CbGeAlD
Fulvestrant—ESRRA—parotid gland—peripheral nervous system neoplasm	0.00481	0.0907	CbGeAlD
Fulvestrant—NR1H4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.00437	0.0278	CbGpPWpGaD
Fulvestrant—NR1H4—Orphan transporters—COX2—peripheral nervous system neoplasm	0.00427	0.0272	CbGpPWpGaD
Fulvestrant—NR1H4—Fatty acid, triacylglycerol, and ketone body metabolism—HSD17B12—peripheral nervous system neoplasm	0.00413	0.0263	CbGpPWpGaD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NF1—peripheral nervous system neoplasm	0.00284	0.0181	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00282	0.0179	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—NTS—peripheral nervous system neoplasm	0.00279	0.0178	CbGpPWpGaD
Fulvestrant—ESR2—brainstem—peripheral nervous system neoplasm	0.00271	0.0511	CbGeAlD
Fulvestrant—ESR1—Estrogen signaling pathway—GNAS—peripheral nervous system neoplasm	0.00267	0.017	CbGpPWpGaD
Fulvestrant—EPHX2—cerebellum—peripheral nervous system neoplasm	0.00254	0.0479	CbGeAlD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00238	0.0151	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—NF1—peripheral nervous system neoplasm	0.00233	0.0148	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00225	0.0143	CbGpPWpGaD
Fulvestrant—ESRRA—cerebellum—peripheral nervous system neoplasm	0.00223	0.0419	CbGeAlD
Fulvestrant—CYP3A4—Codeine and Morphine Metabolism—ABCB1—peripheral nervous system neoplasm	0.00199	0.0127	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—CHEK2—peripheral nervous system neoplasm	0.00197	0.0126	CbGpPWpGaD
Fulvestrant—ESR1—brainstem—peripheral nervous system neoplasm	0.00186	0.035	CbGeAlD
Fulvestrant—EPHX2—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00186	0.0118	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—BARD1—peripheral nervous system neoplasm	0.00177	0.0113	CbGpPWpGaD
Fulvestrant—CYP3A4—Irinotecan Pathway—BCHE—peripheral nervous system neoplasm	0.00169	0.0107	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—HSD17B12—peripheral nervous system neoplasm	0.00164	0.0105	CbGpPWpGaD
Fulvestrant—ESR1—ATF-2 transcription factor network—TH—peripheral nervous system neoplasm	0.00154	0.0098	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—NTRK2—peripheral nervous system neoplasm	0.00153	0.00975	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00148	0.00944	CbGpPWpGaD
Fulvestrant—ESR1—FOXM1 transcription factor network—BIRC5—peripheral nervous system neoplasm	0.00143	0.0091	CbGpPWpGaD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—TH—peripheral nervous system neoplasm	0.0014	0.00893	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—NRAS—peripheral nervous system neoplasm	0.00139	0.00887	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TH—peripheral nervous system neoplasm	0.00134	0.00855	CbGpPWpGaD
Fulvestrant—ESR2—cerebellum—peripheral nervous system neoplasm	0.00134	0.0252	CbGeAlD
Fulvestrant—ESRRA—Gene Expression—EED—peripheral nervous system neoplasm	0.00129	0.0082	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00125	0.00798	CbGpPWpGaD
Fulvestrant—ESR1—Nuclear signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.00122	0.00774	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—IFNB1—peripheral nervous system neoplasm	0.0012	0.00766	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.0012	0.00763	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00116	0.00741	CbGpPWpGaD
Fulvestrant—Pain—Dactinomycin—peripheral nervous system neoplasm	0.00115	0.00146	CcSEcCtD
Fulvestrant—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00115	0.00146	CcSEcCtD
Fulvestrant—Anorexia—Vincristine—peripheral nervous system neoplasm	0.00115	0.00145	CcSEcCtD
Fulvestrant—Hepatic failure—Doxorubicin—peripheral nervous system neoplasm	0.00114	0.00145	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—BDNF—peripheral nervous system neoplasm	0.00114	0.00727	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Alitretinoin—peripheral nervous system neoplasm	0.00114	0.00144	CcSEcCtD
Fulvestrant—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00114	0.00144	CcSEcCtD
Fulvestrant—Insomnia—Alitretinoin—peripheral nervous system neoplasm	0.00113	0.00143	CcSEcCtD
Fulvestrant—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.00113	0.00143	CcSEcCtD
Fulvestrant—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.00113	0.00143	CcSEcCtD
Fulvestrant—Paraesthesia—Alitretinoin—peripheral nervous system neoplasm	0.00112	0.00142	CcSEcCtD
Fulvestrant—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00111	0.00141	CcSEcCtD
Fulvestrant—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00111	0.00141	CcSEcCtD
Fulvestrant—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.00111	0.00141	CcSEcCtD
Fulvestrant—Myalgia—Cisplatin—peripheral nervous system neoplasm	0.00111	0.0014	CcSEcCtD
Fulvestrant—Anxiety—Cisplatin—peripheral nervous system neoplasm	0.0011	0.0014	CcSEcCtD
Fulvestrant—Anaemia—Etoposide—peripheral nervous system neoplasm	0.0011	0.0014	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—peripheral nervous system neoplasm	0.0011	0.00139	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.0011	0.00139	CcSEcCtD
Fulvestrant—Hot flush—Doxorubicin—peripheral nervous system neoplasm	0.0011	0.00139	CcSEcCtD
Fulvestrant—Dyspepsia—Alitretinoin—peripheral nervous system neoplasm	0.0011	0.00139	CcSEcCtD
Fulvestrant—Dizziness—Topotecan—peripheral nervous system neoplasm	0.0011	0.00139	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—NF1—peripheral nervous system neoplasm	0.0011	0.00698	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Vincristine—peripheral nervous system neoplasm	0.00109	0.00139	CcSEcCtD
Fulvestrant—Menopausal symptoms—Doxorubicin—peripheral nervous system neoplasm	0.00109	0.00138	CcSEcCtD
Fulvestrant—CYP3A4—Drug Induction of Bile Acid Pathway—ABCB1—peripheral nervous system neoplasm	0.00109	0.00693	CbGpPWpGaD
Fulvestrant—Dizziness—Tretinoin—peripheral nervous system neoplasm	0.00109	0.00138	CcSEcCtD
Fulvestrant—Dizziness—Isotretinoin—peripheral nervous system neoplasm	0.00109	0.00138	CcSEcCtD
Fulvestrant—Insomnia—Vincristine—peripheral nervous system neoplasm	0.00109	0.00138	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00108	0.0069	CbGpPWpGaD
Fulvestrant—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00137	CcSEcCtD
Fulvestrant—Paraesthesia—Vincristine—peripheral nervous system neoplasm	0.00108	0.00137	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00136	CcSEcCtD
Fulvestrant—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.00108	0.00136	CcSEcCtD
Fulvestrant—Vertigo—Etoposide—peripheral nervous system neoplasm	0.00107	0.00136	CcSEcCtD
Fulvestrant—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.00107	0.00135	CcSEcCtD
Fulvestrant—Pain—Alitretinoin—peripheral nervous system neoplasm	0.00107	0.00135	CcSEcCtD
Fulvestrant—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00107	0.00135	CcSEcCtD
Fulvestrant—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00106	0.00135	CcSEcCtD
Fulvestrant—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.00106	0.00135	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.00106	0.00676	CbGpPWpGaD
Fulvestrant—Infection—Cisplatin—peripheral nervous system neoplasm	0.00106	0.00134	CcSEcCtD
Fulvestrant—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00105	0.00134	CcSEcCtD
Fulvestrant—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00105	0.00133	CcSEcCtD
Fulvestrant—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00105	0.00133	CcSEcCtD
Fulvestrant—Rash—Topotecan—peripheral nervous system neoplasm	0.00105	0.00132	CcSEcCtD
Fulvestrant—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00105	0.00132	CcSEcCtD
Fulvestrant—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00104	0.00132	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—COX2—peripheral nervous system neoplasm	0.00104	0.00664	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Cisplatin—peripheral nervous system neoplasm	0.00104	0.00132	CcSEcCtD
Fulvestrant—EPHX2—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.00104	0.00663	CbGpPWpGaD
Fulvestrant—Cough—Etoposide—peripheral nervous system neoplasm	0.00104	0.00132	CcSEcCtD
Fulvestrant—Headache—Topotecan—peripheral nervous system neoplasm	0.00104	0.00132	CcSEcCtD
Fulvestrant—Rash—Tretinoin—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Vincristine—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Fatigue—Vincristine—peripheral nervous system neoplasm	0.00104	0.00131	CcSEcCtD
Fulvestrant—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00103	0.00131	CcSEcCtD
Fulvestrant—Skin disorder—Cisplatin—peripheral nervous system neoplasm	0.00103	0.00131	CcSEcCtD
Fulvestrant—Headache—Tretinoin—peripheral nervous system neoplasm	0.00103	0.00131	CcSEcCtD
Fulvestrant—Headache—Isotretinoin—peripheral nervous system neoplasm	0.00103	0.00131	CcSEcCtD
Fulvestrant—ESRRA—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.00103	0.00656	CbGpPWpGaD
Fulvestrant—Pain—Vincristine—peripheral nervous system neoplasm	0.00103	0.0013	CcSEcCtD
Fulvestrant—Constipation—Vincristine—peripheral nervous system neoplasm	0.00103	0.0013	CcSEcCtD
Fulvestrant—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.00103	0.0013	CcSEcCtD
Fulvestrant—Hyperhidrosis—Cisplatin—peripheral nervous system neoplasm	0.00103	0.0013	CcSEcCtD
Fulvestrant—Rash—Melphalan—peripheral nervous system neoplasm	0.00102	0.0013	CcSEcCtD
Fulvestrant—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00102	0.0013	CcSEcCtD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—HRAS—peripheral nervous system neoplasm	0.00102	0.00649	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00102	0.00129	CcSEcCtD
Fulvestrant—Chest pain—Etoposide—peripheral nervous system neoplasm	0.00102	0.00129	CcSEcCtD
Fulvestrant—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.00101	0.00128	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Etoposide—peripheral nervous system neoplasm	0.00101	0.00128	CcSEcCtD
Fulvestrant—Breast disorder—Epirubicin—peripheral nervous system neoplasm	0.001	0.00127	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.001	0.00638	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Dactinomycin—peripheral nervous system neoplasm	0.000991	0.00125	CcSEcCtD
Fulvestrant—Urticaria—Alitretinoin—peripheral nervous system neoplasm	0.000991	0.00125	CcSEcCtD
Fulvestrant—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.000986	0.00125	CcSEcCtD
Fulvestrant—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.000986	0.00125	CcSEcCtD
Fulvestrant—Nausea—Topotecan—peripheral nervous system neoplasm	0.000985	0.00125	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.000983	0.00124	CcSEcCtD
Fulvestrant—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.000978	0.00124	CcSEcCtD
Fulvestrant—Nausea—Tretinoin—peripheral nervous system neoplasm	0.000978	0.00124	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000972	0.00619	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Cisplatin—peripheral nervous system neoplasm	0.000968	0.00123	CcSEcCtD
Fulvestrant—Infection—Etoposide—peripheral nervous system neoplasm	0.000967	0.00122	CcSEcCtD
Fulvestrant—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.000965	0.00122	CcSEcCtD
Fulvestrant—Nausea—Melphalan—peripheral nervous system neoplasm	0.000965	0.00122	CcSEcCtD
Fulvestrant—Influenza—Epirubicin—peripheral nervous system neoplasm	0.00096	0.00122	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000956	0.00608	CbGpPWpGaD
Fulvestrant—Paraesthesia—Cisplatin—peripheral nervous system neoplasm	0.000954	0.00121	CcSEcCtD
Fulvestrant—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00095	0.0012	CcSEcCtD
Fulvestrant—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00095	0.0012	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.000948	0.00603	CbGpPWpGaD
Fulvestrant—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.000947	0.0012	CcSEcCtD
Fulvestrant—Skin disorder—Etoposide—peripheral nervous system neoplasm	0.000946	0.0012	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—EED—peripheral nervous system neoplasm	0.000942	0.00599	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Etoposide—peripheral nervous system neoplasm	0.000941	0.00119	CcSEcCtD
Fulvestrant—Breast disorder—Doxorubicin—peripheral nervous system neoplasm	0.000928	0.00118	CcSEcCtD
Fulvestrant—Anorexia—Etoposide—peripheral nervous system neoplasm	0.000928	0.00118	CcSEcCtD
Fulvestrant—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.000924	0.00117	CcSEcCtD
Fulvestrant—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00092	0.00117	CcSEcCtD
Fulvestrant—Hypersensitivity—Alitretinoin—peripheral nervous system neoplasm	0.000919	0.00116	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Cisplatin—peripheral nervous system neoplasm	0.000917	0.00116	CcSEcCtD
Fulvestrant—ESR1—cerebellum—peripheral nervous system neoplasm	0.000915	0.0172	CbGeAlD
Fulvestrant—ESR2—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.00091	0.00579	CbGpPWpGaD
Fulvestrant—Pain—Cisplatin—peripheral nervous system neoplasm	0.000909	0.00115	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GNS—peripheral nervous system neoplasm	0.000906	0.00577	CbGpPWpGaD
Fulvestrant—ESR2—Plasma membrane estrogen receptor signaling—AKT1—peripheral nervous system neoplasm	0.000901	0.00573	CbGpPWpGaD
Fulvestrant—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.000895	0.00113	CcSEcCtD
Fulvestrant—Influenza—Doxorubicin—peripheral nervous system neoplasm	0.000888	0.00112	CcSEcCtD
Fulvestrant—Hypersensitivity—Vincristine—peripheral nervous system neoplasm	0.000885	0.00112	CcSEcCtD
Fulvestrant—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.000882	0.00112	CcSEcCtD
Fulvestrant—Paraesthesia—Etoposide—peripheral nervous system neoplasm	0.000874	0.00111	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—NME1—peripheral nervous system neoplasm	0.000869	0.00553	CbGpPWpGaD
Fulvestrant—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.000868	0.0011	CcSEcCtD
Fulvestrant—Asthenia—Vincristine—peripheral nervous system neoplasm	0.000862	0.00109	CcSEcCtD
Fulvestrant—Infestation—Epirubicin—peripheral nervous system neoplasm	0.000856	0.00108	CcSEcCtD
Fulvestrant—Infestation NOS—Epirubicin—peripheral nervous system neoplasm	0.000856	0.00108	CcSEcCtD
Fulvestrant—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.000855	0.00108	CcSEcCtD
Fulvestrant—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.000853	0.00108	CcSEcCtD
Fulvestrant—Rash—Dactinomycin—peripheral nervous system neoplasm	0.000848	0.00107	CcSEcCtD
Fulvestrant—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.000846	0.00107	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Etoposide—peripheral nervous system neoplasm	0.000841	0.00106	CcSEcCtD
Fulvestrant—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00084	0.00106	CcSEcCtD
Fulvestrant—Fatigue—Etoposide—peripheral nervous system neoplasm	0.000839	0.00106	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—COX2—peripheral nervous system neoplasm	0.000837	0.00532	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000833	0.0053	CbGpPWpGaD
Fulvestrant—Pain—Etoposide—peripheral nervous system neoplasm	0.000833	0.00105	CcSEcCtD
Fulvestrant—Constipation—Etoposide—peripheral nervous system neoplasm	0.000833	0.00105	CcSEcCtD
Fulvestrant—Urinary tract infection—Epirubicin—peripheral nervous system neoplasm	0.000832	0.00105	CcSEcCtD
Fulvestrant—Dizziness—Alitretinoin—peripheral nervous system neoplasm	0.000825	0.00104	CcSEcCtD
Fulvestrant—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.000822	0.00104	CcSEcCtD
Fulvestrant—ESR2—Gene Expression—EED—peripheral nervous system neoplasm	0.00082	0.00522	CbGpPWpGaD
Fulvestrant—Sweating—Epirubicin—peripheral nervous system neoplasm	0.00082	0.00104	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Epirubicin—peripheral nervous system neoplasm	0.000809	0.00102	CcSEcCtD
Fulvestrant—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.000799	0.00101	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.000796	0.00101	CcSEcCtD
Fulvestrant—Dizziness—Vincristine—peripheral nervous system neoplasm	0.000795	0.00101	CcSEcCtD
Fulvestrant—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.000793	0.001	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AURKA—peripheral nervous system neoplasm	0.000793	0.00504	CbGpPWpGaD
Fulvestrant—Infestation NOS—Doxorubicin—peripheral nervous system neoplasm	0.000792	0.001	CcSEcCtD
Fulvestrant—Infestation—Doxorubicin—peripheral nervous system neoplasm	0.000792	0.001	CcSEcCtD
Fulvestrant—Rash—Alitretinoin—peripheral nervous system neoplasm	0.000786	0.000996	CcSEcCtD
Fulvestrant—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.000786	0.000995	CcSEcCtD
Fulvestrant—Hypersensitivity—Cisplatin—peripheral nervous system neoplasm	0.000783	0.000991	CcSEcCtD
Fulvestrant—Headache—Alitretinoin—peripheral nervous system neoplasm	0.000781	0.000989	CcSEcCtD
Fulvestrant—Urticaria—Etoposide—peripheral nervous system neoplasm	0.000773	0.000979	CcSEcCtD
Fulvestrant—Haemoglobin—Epirubicin—peripheral nervous system neoplasm	0.000772	0.000978	CcSEcCtD
Fulvestrant—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00077	0.000975	CcSEcCtD
Fulvestrant—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00077	0.000975	CcSEcCtD
Fulvestrant—Urinary tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00077	0.000974	CcSEcCtD
Fulvestrant—Haemorrhage—Epirubicin—peripheral nervous system neoplasm	0.000768	0.000973	CcSEcCtD
Fulvestrant—Hepatitis—Epirubicin—peripheral nervous system neoplasm	0.000768	0.000973	CcSEcCtD
Fulvestrant—Vomiting—Vincristine—peripheral nervous system neoplasm	0.000764	0.000968	CcSEcCtD
Fulvestrant—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.000762	0.000965	CcSEcCtD
Fulvestrant—Pharyngitis—Epirubicin—peripheral nervous system neoplasm	0.000762	0.000965	CcSEcCtD
Fulvestrant—Sweating—Doxorubicin—peripheral nervous system neoplasm	0.000759	0.000961	CcSEcCtD
Fulvestrant—Rash—Vincristine—peripheral nervous system neoplasm	0.000758	0.00096	CcSEcCtD
Fulvestrant—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.000757	0.000959	CcSEcCtD
Fulvestrant—Oedema peripheral—Epirubicin—peripheral nervous system neoplasm	0.000757	0.000958	CcSEcCtD
Fulvestrant—Connective tissue disorder—Epirubicin—peripheral nervous system neoplasm	0.000755	0.000956	CcSEcCtD
Fulvestrant—NR1H4—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000753	0.00479	CbGpPWpGaD
Fulvestrant—Headache—Vincristine—peripheral nervous system neoplasm	0.000753	0.000953	CcSEcCtD
Fulvestrant—Hepatobiliary disease—Doxorubicin—peripheral nervous system neoplasm	0.000749	0.000948	CcSEcCtD
Fulvestrant—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.000741	0.000938	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000732	0.00466	CbGpPWpGaD
Fulvestrant—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.000727	0.000921	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—GNS—peripheral nervous system neoplasm	0.000725	0.00461	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—PTPN11—peripheral nervous system neoplasm	0.000721	0.00459	CbGpPWpGaD
Fulvestrant—ESR1—Estrogen signaling pathway—AKT1—peripheral nervous system neoplasm	0.000721	0.00459	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Etoposide—peripheral nervous system neoplasm	0.000717	0.000908	CcSEcCtD
Fulvestrant—Haemoglobin—Doxorubicin—peripheral nervous system neoplasm	0.000714	0.000905	CcSEcCtD
Fulvestrant—Nausea—Vincristine—peripheral nervous system neoplasm	0.000714	0.000904	CcSEcCtD
Fulvestrant—Hepatitis—Doxorubicin—peripheral nervous system neoplasm	0.000711	0.0009	CcSEcCtD
Fulvestrant—Haemorrhage—Doxorubicin—peripheral nervous system neoplasm	0.000711	0.0009	CcSEcCtD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000709	0.00451	CbGpPWpGaD
Fulvestrant—Pharyngitis—Doxorubicin—peripheral nervous system neoplasm	0.000705	0.000893	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—NRAS—peripheral nervous system neoplasm	0.000703	0.00447	CbGpPWpGaD
Fulvestrant—Oedema peripheral—Doxorubicin—peripheral nervous system neoplasm	0.0007	0.000887	CcSEcCtD
Fulvestrant—Asthenia—Etoposide—peripheral nervous system neoplasm	0.000699	0.000885	CcSEcCtD
Fulvestrant—Connective tissue disorder—Doxorubicin—peripheral nervous system neoplasm	0.000698	0.000884	CcSEcCtD
Fulvestrant—Angiopathy—Epirubicin—peripheral nervous system neoplasm	0.000697	0.000882	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—NME1—peripheral nervous system neoplasm	0.000695	0.00442	CbGpPWpGaD
Fulvestrant—Immune system disorder—Epirubicin—peripheral nervous system neoplasm	0.000694	0.000879	CcSEcCtD
Fulvestrant—Pruritus—Etoposide—peripheral nervous system neoplasm	0.000689	0.000872	CcSEcCtD
Fulvestrant—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.000676	0.000856	CcSEcCtD
Fulvestrant—Rash—Cisplatin—peripheral nervous system neoplasm	0.00067	0.000848	CcSEcCtD
Fulvestrant—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.000669	0.000848	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—COX2—peripheral nervous system neoplasm	0.000669	0.00426	CbGpPWpGaD
Fulvestrant—Malnutrition—Epirubicin—peripheral nervous system neoplasm	0.000669	0.000847	CcSEcCtD
Fulvestrant—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.000666	0.000843	CcSEcCtD
Fulvestrant—CYP3A4—Constitutive Androstane Receptor Pathway—ABCB1—peripheral nervous system neoplasm	0.000656	0.00418	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000656	0.00417	CbGpPWpGaD
Fulvestrant—Back pain—Epirubicin—peripheral nervous system neoplasm	0.000647	0.000819	CcSEcCtD
Fulvestrant—Angiopathy—Doxorubicin—peripheral nervous system neoplasm	0.000645	0.000817	CcSEcCtD
Fulvestrant—Dizziness—Etoposide—peripheral nervous system neoplasm	0.000644	0.000815	CcSEcCtD
Fulvestrant—ESR1—FOXM1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000642	0.00409	CbGpPWpGaD
Fulvestrant—Immune system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000642	0.000813	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—NRAS—peripheral nervous system neoplasm	0.000641	0.00408	CbGpPWpGaD
Fulvestrant—Nausea—Cisplatin—peripheral nervous system neoplasm	0.000631	0.000799	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—MYC—peripheral nervous system neoplasm	0.00063	0.00401	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00063	0.00401	CbGpPWpGaD
Fulvestrant—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—ABCB1—peripheral nervous system neoplasm	0.000625	0.00398	CbGpPWpGaD
Fulvestrant—Vomiting—Etoposide—peripheral nervous system neoplasm	0.000619	0.000784	CcSEcCtD
Fulvestrant—Malnutrition—Doxorubicin—peripheral nervous system neoplasm	0.000619	0.000783	CcSEcCtD
Fulvestrant—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.000618	0.000783	CcSEcCtD
Fulvestrant—Rash—Etoposide—peripheral nervous system neoplasm	0.000614	0.000777	CcSEcCtD
Fulvestrant—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.000613	0.000777	CcSEcCtD
Fulvestrant—ESR1—Signaling mediated by p38-alpha and p38-beta—TP53—peripheral nervous system neoplasm	0.00061	0.00388	CbGpPWpGaD
Fulvestrant—Headache—Etoposide—peripheral nervous system neoplasm	0.00061	0.000772	CcSEcCtD
Fulvestrant—NR1H4—Metabolism of lipids and lipoproteins—BCHE—peripheral nervous system neoplasm	0.000609	0.00387	CbGpPWpGaD
Fulvestrant—Vertigo—Epirubicin—peripheral nervous system neoplasm	0.000601	0.000761	CcSEcCtD
Fulvestrant—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.000599	0.000758	CcSEcCtD
Fulvestrant—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.000598	0.000758	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—MYC—peripheral nervous system neoplasm	0.000597	0.0038	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.000587	0.00374	CbGpPWpGaD
Fulvestrant—Cough—Epirubicin—peripheral nervous system neoplasm	0.000584	0.000739	CcSEcCtD
Fulvestrant—Nausea—Etoposide—peripheral nervous system neoplasm	0.000578	0.000732	CcSEcCtD
Fulvestrant—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.000572	0.000724	CcSEcCtD
Fulvestrant—ESR2—SIDS Susceptibility Pathways—CASP3—peripheral nervous system neoplasm	0.000571	0.00363	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—ERBB2—peripheral nervous system neoplasm	0.00057	0.00363	CbGpPWpGaD
Fulvestrant—Myalgia—Epirubicin—peripheral nervous system neoplasm	0.000569	0.000721	CcSEcCtD
Fulvestrant—Chest pain—Epirubicin—peripheral nervous system neoplasm	0.000569	0.000721	CcSEcCtD
Fulvestrant—Arthralgia—Epirubicin—peripheral nervous system neoplasm	0.000569	0.000721	CcSEcCtD
Fulvestrant—Anxiety—Epirubicin—peripheral nervous system neoplasm	0.000567	0.000718	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—peripheral nervous system neoplasm	0.000565	0.000716	CcSEcCtD
Fulvestrant—Vertigo—Doxorubicin—peripheral nervous system neoplasm	0.000556	0.000704	CcSEcCtD
Fulvestrant—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.000554	0.000701	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—SLC2A1—peripheral nervous system neoplasm	0.000552	0.00351	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ENO2—peripheral nervous system neoplasm	0.000549	0.00349	CbGpPWpGaD
Fulvestrant—Infection—Epirubicin—peripheral nervous system neoplasm	0.000542	0.000687	CcSEcCtD
Fulvestrant—Cough—Doxorubicin—peripheral nervous system neoplasm	0.00054	0.000684	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.000535	0.00341	CbGpPWpGaD
Fulvestrant—Nervous system disorder—Epirubicin—peripheral nervous system neoplasm	0.000535	0.000678	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000535	0.00341	CbGpPWpGaD
Fulvestrant—Skin disorder—Epirubicin—peripheral nervous system neoplasm	0.00053	0.000671	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—GNS—peripheral nervous system neoplasm	0.00053	0.00337	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Epirubicin—peripheral nervous system neoplasm	0.000528	0.000668	CcSEcCtD
Fulvestrant—Arthralgia—Doxorubicin—peripheral nervous system neoplasm	0.000527	0.000667	CcSEcCtD
Fulvestrant—Chest pain—Doxorubicin—peripheral nervous system neoplasm	0.000527	0.000667	CcSEcCtD
Fulvestrant—Myalgia—Doxorubicin—peripheral nervous system neoplasm	0.000527	0.000667	CcSEcCtD
Fulvestrant—Anxiety—Doxorubicin—peripheral nervous system neoplasm	0.000525	0.000665	CcSEcCtD
Fulvestrant—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—peripheral nervous system neoplasm	0.000523	0.000662	CcSEcCtD
Fulvestrant—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.00052	0.000659	CcSEcCtD
Fulvestrant—ESR1—LKB1 signaling events—TP53—peripheral nervous system neoplasm	0.000518	0.00329	CbGpPWpGaD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—HRAS—peripheral nervous system neoplasm	0.000514	0.00327	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—NME1—peripheral nervous system neoplasm	0.000508	0.00323	CbGpPWpGaD
Fulvestrant—Infection—Doxorubicin—peripheral nervous system neoplasm	0.000502	0.000635	CcSEcCtD
Fulvestrant—Musculoskeletal discomfort—Epirubicin—peripheral nervous system neoplasm	0.000497	0.00063	CcSEcCtD
Fulvestrant—Nervous system disorder—Doxorubicin—peripheral nervous system neoplasm	0.000495	0.000627	CcSEcCtD
Fulvestrant—Insomnia—Epirubicin—peripheral nervous system neoplasm	0.000494	0.000625	CcSEcCtD
Fulvestrant—Skin disorder—Doxorubicin—peripheral nervous system neoplasm	0.00049	0.000621	CcSEcCtD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.00049	0.00312	CbGpPWpGaD
Fulvestrant—Paraesthesia—Epirubicin—peripheral nervous system neoplasm	0.00049	0.000621	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—COX2—peripheral nervous system neoplasm	0.000489	0.00311	CbGpPWpGaD
Fulvestrant—Hyperhidrosis—Doxorubicin—peripheral nervous system neoplasm	0.000488	0.000618	CcSEcCtD
Fulvestrant—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000487	0.000616	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000486	0.00309	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000482	0.00307	CbGpPWpGaD
Fulvestrant—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000481	0.000609	CcSEcCtD
Fulvestrant—Dyspepsia—Epirubicin—peripheral nervous system neoplasm	0.00048	0.000608	CcSEcCtD
Fulvestrant—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000474	0.000601	CcSEcCtD
Fulvestrant—Gastrointestinal disorder—Epirubicin—peripheral nervous system neoplasm	0.000471	0.000597	CcSEcCtD
Fulvestrant—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000471	0.000596	CcSEcCtD
Fulvestrant—ESR1—Aryl Hydrocarbon Receptor—HRAS—peripheral nervous system neoplasm	0.000469	0.00298	CbGpPWpGaD
Fulvestrant—Pain—Epirubicin—peripheral nervous system neoplasm	0.000467	0.000591	CcSEcCtD
Fulvestrant—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000467	0.000591	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—BCHE—peripheral nervous system neoplasm	0.000464	0.00295	CbGpPWpGaD
Fulvestrant—Musculoskeletal discomfort—Doxorubicin—peripheral nervous system neoplasm	0.00046	0.000583	CcSEcCtD
Fulvestrant—ESR1—Validated nuclear estrogen receptor alpha network—MYC—peripheral nervous system neoplasm	0.000459	0.00292	CbGpPWpGaD
Fulvestrant—Insomnia—Doxorubicin—peripheral nervous system neoplasm	0.000457	0.000578	CcSEcCtD
Fulvestrant—ESR1—Plasma membrane estrogen receptor signaling—AKT1—peripheral nervous system neoplasm	0.000454	0.00289	CbGpPWpGaD
Fulvestrant—Paraesthesia—Doxorubicin—peripheral nervous system neoplasm	0.000453	0.000574	CcSEcCtD
Fulvestrant—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.00045	0.00057	CcSEcCtD
Fulvestrant—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000446	0.000565	CcSEcCtD
Fulvestrant—Dyspepsia—Doxorubicin—peripheral nervous system neoplasm	0.000444	0.000563	CcSEcCtD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—GNAS—peripheral nervous system neoplasm	0.000444	0.00283	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000443	0.00282	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ENO2—peripheral nervous system neoplasm	0.000439	0.00279	CbGpPWpGaD
Fulvestrant—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000439	0.000556	CcSEcCtD
Fulvestrant—ESR1—Regulation of Telomerase—MYC—peripheral nervous system neoplasm	0.000437	0.00278	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—TH—peripheral nervous system neoplasm	0.000436	0.00278	CbGpPWpGaD
Fulvestrant—NR1H4—Transmembrane transport of small molecules—ABCB1—peripheral nervous system neoplasm	0.000436	0.00277	CbGpPWpGaD
Fulvestrant—Gastrointestinal disorder—Doxorubicin—peripheral nervous system neoplasm	0.000436	0.000552	CcSEcCtD
Fulvestrant—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000435	0.000551	CcSEcCtD
Fulvestrant—Urticaria—Epirubicin—peripheral nervous system neoplasm	0.000434	0.000549	CcSEcCtD
Fulvestrant—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000432	0.000547	CcSEcCtD
Fulvestrant—Pain—Doxorubicin—peripheral nervous system neoplasm	0.000432	0.000547	CcSEcCtD
Fulvestrant—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000431	0.000546	CcSEcCtD
Fulvestrant—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000431	0.000546	CcSEcCtD
Fulvestrant—ESR1—AP-1 transcription factor network—MYC—peripheral nervous system neoplasm	0.000427	0.00272	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—EED—peripheral nervous system neoplasm	0.000414	0.00263	CbGpPWpGaD
Fulvestrant—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000413	0.000523	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—PTPN11—peripheral nervous system neoplasm	0.00041	0.00261	CbGpPWpGaD
Fulvestrant—Hypersensitivity—Epirubicin—peripheral nervous system neoplasm	0.000402	0.000509	CcSEcCtD
Fulvestrant—Urticaria—Doxorubicin—peripheral nervous system neoplasm	0.000401	0.000508	CcSEcCtD
Fulvestrant—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000399	0.000505	CcSEcCtD
Fulvestrant—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000399	0.000505	CcSEcCtD
Fulvestrant—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.000392	0.000496	CcSEcCtD
Fulvestrant—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000386	0.000489	CcSEcCtD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—MYC—peripheral nervous system neoplasm	0.00038	0.00242	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000379	0.00241	CbGpPWpGaD
Fulvestrant—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000373	0.000473	CcSEcCtD
Fulvestrant—Hypersensitivity—Doxorubicin—peripheral nervous system neoplasm	0.000372	0.000471	CcSEcCtD
Fulvestrant—ESRRA—Metabolism—BCHE—peripheral nervous system neoplasm	0.000371	0.00236	CbGpPWpGaD
Fulvestrant—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.000362	0.000459	CcSEcCtD
Fulvestrant—Dizziness—Epirubicin—peripheral nervous system neoplasm	0.000361	0.000457	CcSEcCtD
Fulvestrant—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.000357	0.000452	CcSEcCtD
Fulvestrant—EPHX2—Metabolism—GNAS—peripheral nervous system neoplasm	0.000356	0.00227	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000354	0.00225	CbGpPWpGaD
Fulvestrant—ESR1—AP-1 transcription factor network—TP53—peripheral nervous system neoplasm	0.000351	0.00223	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—ABCB1—peripheral nervous system neoplasm	0.00035	0.00222	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—TH—peripheral nervous system neoplasm	0.000349	0.00222	CbGpPWpGaD
Fulvestrant—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000347	0.000439	CcSEcCtD
Fulvestrant—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000345	0.000437	CcSEcCtD
Fulvestrant—Rash—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000436	CcSEcCtD
Fulvestrant—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000344	0.000435	CcSEcCtD
Fulvestrant—Headache—Epirubicin—peripheral nervous system neoplasm	0.000342	0.000433	CcSEcCtD
Fulvestrant—Dizziness—Doxorubicin—peripheral nervous system neoplasm	0.000334	0.000423	CcSEcCtD
Fulvestrant—ESR1—Gene Expression—SUZ12—peripheral nervous system neoplasm	0.000331	0.0021	CbGpPWpGaD
Fulvestrant—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000324	0.00041	CcSEcCtD
Fulvestrant—ESR1—Signaling by ERBB4—ERBB2—peripheral nervous system neoplasm	0.000324	0.00206	CbGpPWpGaD
Fulvestrant—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000321	0.000407	CcSEcCtD
Fulvestrant—NR1H4—Metabolism—ENO2—peripheral nervous system neoplasm	0.000321	0.00204	CbGpPWpGaD
Fulvestrant—Rash—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000403	CcSEcCtD
Fulvestrant—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.000318	0.000403	CcSEcCtD
Fulvestrant—ESR1—Leptin signaling pathway—HRAS—peripheral nervous system neoplasm	0.000317	0.00202	CbGpPWpGaD
Fulvestrant—Headache—Doxorubicin—peripheral nervous system neoplasm	0.000316	0.000401	CcSEcCtD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000311	0.00198	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of Telomerase—AKT1—peripheral nervous system neoplasm	0.000303	0.00193	CbGpPWpGaD
Fulvestrant—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.0003	0.00038	CcSEcCtD
Fulvestrant—ESRRA—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000296	0.00188	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000296	0.00188	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—GNAS—peripheral nervous system neoplasm	0.000285	0.00181	CbGpPWpGaD
Fulvestrant—ESR1—Leptin signaling pathway—AKT1—peripheral nervous system neoplasm	0.00028	0.00178	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000279	0.00178	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—BCHE—peripheral nervous system neoplasm	0.000271	0.00172	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.00027	0.00172	CbGpPWpGaD
Fulvestrant—ESR1—Regulation of nuclear SMAD2/3 signaling—AKT1—peripheral nervous system neoplasm	0.000263	0.00168	CbGpPWpGaD
Fulvestrant—ESR2—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000263	0.00167	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000259	0.00165	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—TH—peripheral nervous system neoplasm	0.000255	0.00162	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—NRAS—peripheral nervous system neoplasm	0.000246	0.00157	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000245	0.00156	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000231	0.00147	CbGpPWpGaD
Fulvestrant—NR1H4—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000216	0.00138	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—GNAS—peripheral nervous system neoplasm	0.000208	0.00132	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000204	0.0013	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NTS—peripheral nervous system neoplasm	0.000194	0.00124	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.000191	0.00122	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—TP53—peripheral nervous system neoplasm	0.00019	0.00121	CbGpPWpGaD
Fulvestrant—ESR2—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	0.000188	0.0012	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CD55—peripheral nervous system neoplasm	0.000186	0.00119	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—HRAS—peripheral nervous system neoplasm	0.00018	0.00115	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Breast Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.00016	0.00102	CbGpPWpGaD
Fulvestrant—ESR1—Signaling by ERBB4—AKT1—peripheral nervous system neoplasm	0.000159	0.00101	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000157	0.000999	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.000155	0.000988	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—VIP—peripheral nervous system neoplasm	0.000147	0.000938	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—MYC—peripheral nervous system neoplasm	0.000143	0.000907	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PPP3R1—peripheral nervous system neoplasm	0.000136	0.000865	CbGpPWpGaD
Fulvestrant—ESR1—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000133	0.000844	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000105	0.000667	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—MYC—peripheral nervous system neoplasm	0.000104	0.000663	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NTRK2—peripheral nervous system neoplasm	0.000102	0.00065	CbGpPWpGaD
Fulvestrant—ESRRA—Gene Expression—AKT1—peripheral nervous system neoplasm	9.88e-05	0.000629	CbGpPWpGaD
Fulvestrant—EPHX2—Metabolism—AKT1—peripheral nervous system neoplasm	9.61e-05	0.000612	CbGpPWpGaD
Fulvestrant—ESR1—Generic Transcription Pathway—MYC—peripheral nervous system neoplasm	9.5e-05	0.000604	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—MYC—peripheral nervous system neoplasm	9.07e-05	0.000577	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—KNG1—peripheral nervous system neoplasm	8.74e-05	0.000556	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NTRK1—peripheral nervous system neoplasm	8.33e-05	0.00053	CbGpPWpGaD
Fulvestrant—ESRRA—Metabolism—AKT1—peripheral nervous system neoplasm	7.69e-05	0.000489	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—GNAS—peripheral nervous system neoplasm	7.64e-05	0.000486	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GNS—peripheral nervous system neoplasm	7.58e-05	0.000482	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—NME1—peripheral nervous system neoplasm	7.27e-05	0.000462	CbGpPWpGaD
Fulvestrant—NR1H4—Gene Expression—AKT1—peripheral nervous system neoplasm	7.22e-05	0.00046	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—COX2—peripheral nervous system neoplasm	7e-05	0.000445	CbGpPWpGaD
Fulvestrant—ESR2—Gene Expression—AKT1—peripheral nervous system neoplasm	6.29e-05	0.0004	CbGpPWpGaD
Fulvestrant—NR1H4—Metabolism—AKT1—peripheral nervous system neoplasm	5.62e-05	0.000357	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—PTPN11—peripheral nervous system neoplasm	5.31e-05	0.000338	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ENO2—peripheral nervous system neoplasm	4.59e-05	0.000292	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—MYC—peripheral nervous system neoplasm	4.57e-05	0.000291	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—ERBB2—peripheral nervous system neoplasm	4.2e-05	0.000267	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—BCHE—peripheral nervous system neoplasm	3.88e-05	0.000247	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—CASP3—peripheral nervous system neoplasm	3.81e-05	0.000242	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—SLC2A1—peripheral nervous system neoplasm	3.7e-05	0.000236	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—TH—peripheral nervous system neoplasm	3.65e-05	0.000232	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—NRAS—peripheral nervous system neoplasm	3.19e-05	0.000203	CbGpPWpGaD
Fulvestrant—ESR1—Gene Expression—AKT1—peripheral nervous system neoplasm	3.17e-05	0.000202	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—GNAS—peripheral nervous system neoplasm	2.98e-05	0.00019	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—MYC—peripheral nervous system neoplasm	2.97e-05	0.000189	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—ABCB1—peripheral nervous system neoplasm	2.92e-05	0.000186	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—TP53—peripheral nervous system neoplasm	2.44e-05	0.000155	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—HRAS—peripheral nervous system neoplasm	2.34e-05	0.000149	CbGpPWpGaD
Fulvestrant—ESR1—Signaling Pathways—AKT1—peripheral nervous system neoplasm	2.06e-05	0.000131	CbGpPWpGaD
Fulvestrant—CYP3A4—Metabolism—AKT1—peripheral nervous system neoplasm	8.04e-06	5.12e-05	CbGpPWpGaD
